Genetic Testing (PGT/PGD) in Haryana: A Complete Clinical Guide for Fertility Patients

Preimplantation Genetic Testing (PGT) is a laboratory procedure performed on embryos created through IVF before they are transferred into the uterus. The umbrella term PGT encompasses three specific tests: PGT-A (for chromosomal aneuploidies), PGT-M (for monogenic or single-gene disorders, previously called PGD), and PGT-SR (for structural chromosomal rearrangements).

During a standard IVF cycle, eggs are retrieved, fertilised in the lab, and cultured to the blastocyst stage — usually Day 5 or Day 6. At this point, an embryologist performs a biopsy, carefully removing 5–8 cells from the trophectoderm (the outer cell layer that eventually forms the placenta). These cells are sent to a genetics laboratory where techniques such as Next-Generation Sequencing (NGS) or Array Comparative Genomic Hybridisation (aCGH) analyse the chromosomal and/or genetic makeup of each embryo.

Only embryos confirmed as chromosomally normal or free of the targeted genetic mutation are selected for transfer. The remaining embryos may be frozen for future cycles. This process does not harm the embryo's developmental potential and is now considered standard of care for many high-risk patient categories by reproductive medicine bodies worldwide, including the Indian Society for Assisted Reproduction (ISAR).

Genetic testing is not universally required for every IVF cycle, but it is strongly recommended for specific patient groups. In Haryana, where consanguineous marriages (marriages among close relatives) occur in certain communities and where carrier rates for haemoglobinopathies like thalassemia are clinically significant, PGT-M (monogenic testing) is particularly relevant.

Clinical indications for PGT include: women aged 35 and above where chromosomal aneuploidy risk rises sharply; couples who have experienced two or more recurrent pregnancy losses (RPL); patients with two or more failed IVF embryo transfer cycles despite good-quality embryos; couples where one or both partners are known carriers of a single-gene disorder such as beta-thalassemia, cystic fibrosis, spinal muscular atrophy, or Duchenne muscular dystrophy; and individuals with known chromosomal structural rearrangements (translocations or inversions).

Fertility specialists across cities like Faridabad, Karnal, and Gurgaon are increasingly incorporating carrier screening into pre-IVF workups. If carrier screening reveals that both partners carry a mutation for the same recessive disorder, PGT-M becomes the most reliable way to avoid having an affected child while also pursuing biological parenthood through IVF.

Many couples do not consider genetic testing until they have already experienced heartbreak — a miscarriage, a child born with a serious illness, or a series of failed IVF transfers. Awareness of warning signs can help Haryana patients seek answers earlier.

Key indicators include: a family history of inherited disorders in either partner's lineage; a previous child born with a chromosomal abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or Patau syndrome (Trisomy 13); unexplained recurrent miscarriages, particularly in the first trimester; advanced maternal age (AMA), typically defined as 35 years or older at egg retrieval; prior IVF cycles that produced high-quality embryos that still failed to implant or resulted in biochemical pregnancies.

For couples in smaller Haryana towns like Rohtak, Sonipat, or Rewari, these signs may go unaddressed for years due to limited access to genetic counsellors. HomeIVF's telehealth infrastructure allows patients from any district to consult with genetic counsellors and reproductive medicine specialists remotely, ensuring that clinical decision-making is not delayed by geography.

Before a PGT cycle can begin, a structured diagnostic protocol is essential. The HomeIVF Medical Board recommends a staged workup that rules out modifiable causes of infertility and establishes the precise genetic indication.

For female partners, baseline investigations include a transvaginal ultrasound (to assess antral follicle count and uterine anatomy), serum AMH (Anti-Müllerian Hormone) to evaluate ovarian reserve, FSH, LH and oestradiol on Day 2–3 of the menstrual cycle, thyroid function tests, and a hysteroscopy if uterine pathology is suspected. For male partners, a semen analysis including morphology and DNA fragmentation index (DFI) is critical — high DNA fragmentation is associated with poor embryo quality and transfer failure.

Genetic-specific tests include: karyotyping of both partners (a chromosomal map), carrier screening panels (which in India often prioritise thalassemia, SMA, and fragile X syndrome), and — if a specific monogenic mutation is known — molecular confirmation of the exact variant. For PGT-M cycles, the genetics laboratory typically requires 8–12 weeks to design a customised probe or haplotyping strategy before the IVF stimulation cycle can begin. Patients in Gurgaon and Faridabad with access to partner labs can often expedite this, while HomeIVF coordinates sample logistics for patients in more remote areas.

A PGT-assisted IVF cycle follows the same foundational steps as a standard IVF cycle but with the addition of embryo biopsy and genetic analysis between egg retrieval and embryo transfer. Here is what the journey looks like:

**Ovarian Stimulation:** The female partner self-administers subcutaneous gonadotropin injections for 10–14 days under close monitoring through serial ultrasounds and hormone tests. HomeIVF's model allows much of this monitoring to happen at or near the patient's home, reducing the burden of travelling to a clinic in Gurgaon or Karnal multiple times per week.

**Egg Retrieval and Fertilisation:** Eggs are retrieved under sedation in a partner clinic's procedure room. Fertilisation is performed via ICSI (Intracytoplasmic Sperm Injection), which is preferred in PGT cycles to avoid contamination of the genetic sample.

**Embryo Culture and Biopsy:** Embryos are cultured to the blastocyst stage. The embryologist performs a trophectoderm biopsy, and samples are dispatched — often to a centralised NGS laboratory — for analysis, which typically takes 10–14 days.

**Frozen Embryo Transfer (FET):** Because biopsy results take time, all PGT cycles use a freeze-all strategy. Once results are confirmed, a euploid (chromosomally normal) embryo is transferred in a subsequent FET cycle, with the uterine lining carefully prepared using oestrogen and progesterone support.

The HomeIVF Medical Board oversees the clinical protocol at every stage, ensuring adherence to ISAR and ESHRE guidelines.

One of the most frequent questions from patients across Haryana is: what does genetic testing add to the cost of an IVF cycle, and is it worth it? The honest answer is that while PGT adds laboratory and biopsy costs to the base IVF investment, it can significantly reduce the number of transfer cycles needed and, more importantly, reduce the emotional and financial toll of miscarriages or a child born with a serious genetic condition.

HomeIVF offers IVF packages starting from ₹1.5 lakh, and the team is transparent about what PGT-specific add-ons entail. For patients in Haryana cities such as Karnal, Panipat, and Faridabad, the HomeIVF coordinator provides a personalised cost breakdown during the initial consultation — accounting for the specific type of PGT required (PGT-A versus PGT-M), the number of embryos to be biopsied, and the genetics laboratory fees.

Timeline-wise, a PGT-A cycle (chromosomal screening) adds approximately 2–3 weeks to the standard IVF cycle due to the freeze-all and biopsy analysis phase. A PGT-M cycle, which requires probe design for a specific mutation, adds a preparatory phase of 8–12 weeks before stimulation begins. Patients are counselled thoroughly on this timeline so they can plan around professional and personal commitments.

One of the most transformative aspects of the HomeIVF model for patients undergoing PGT-assisted cycles in Haryana is the ability to conduct significant portions of the cycle monitoring remotely or at satellite collection points — rather than making repeated long-distance trips to a tertiary fertility centre.

For a couple in Panipat or Rohtak, travelling to a Gurgaon clinic three to four times during the stimulation phase for follicle tracking ultrasounds and blood draws represents a real logistical and financial burden. HomeIVF coordinates with trained sonographers and phlebotomists closer to the patient's location, with reports reviewed in real time by senior reproductive endocrinologists on the platform.

The digital dashboard allows patients to track hormone levels, follicle growth, and medication schedules in one place. Teleconsultation slots are available seven days a week, ensuring that any concern — whether a reaction to stimulation medication or anxiety about biopsy results — is addressed promptly by the HomeIVF Medical Board-supervised clinical team. This is not a replacement for specialist care; it is specialist care delivered with the convenience of technology.

Despite Haryana's proximity to Delhi's world-class medical infrastructure, many patients in the state face significant structural barriers to accessing PGT services. These include: limited availability of genetic counsellors outside major cities like Gurgaon; fragmented care pathways where fertility clinics, genetics labs, and embryology units operate independently without coordination; social stigma around infertility and genetic disorders that prevents couples from seeking timely help; language barriers in clinical communication for patients more comfortable in Haryanvi or Hindi; and financial opacity — many patients are quoted wide cost ranges without a clear breakdown.

HomeIVF addresses each of these barriers systematically. The platform offers consultations in Hindi, provides written treatment summaries in plain language, and assigns a dedicated patient coordinator to each couple — guiding them from initial carrier screening through to embryo transfer. Partnerships with certified genetics laboratories and NABH-accredited procedure centres in Faridabad, Gurgaon, and Karnal mean that the clinical chain of custody for embryo biopsies is rigorously maintained.

For couples in rural Haryana who have historically been told that genetic testing is only possible in Delhi, HomeIVF's networked model is a genuine paradigm shift — bringing the same quality of genetic science to Haryana patients without requiring relocation.